A PDE5 inhibitor developed to target erectile dysfunction and intended to manage urinary symptoms of an enlarged prostate to alleviate related sexual performance issues.
Mechanism of Action
It relaxes the smooth muscles of the blood vessels in the penis and prostate, increasing blood flow and facilitating an erection during sexual stimulation.
Route of Administration
Oral
Onset Time
30–60 minutes
Duration
Up to 36 hours
Contraindications
Concurrent use of nitrates, Severe heart disease, Low blood pressure, Allergy to tadalafil
Information for Vidalista is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
